The Patent Finder

Emcure Pharmaceuticals Limited

Also on record
Records under this name other than the patents Emcure Pharmaceuticals Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.

Back to Emcure Pharmaceuticals Limited

PatentTitleStatus Expires Confidence
US 9,006,453Process for preparation of zolmitriptan
Lapsed on the fee record
Ended Apr 14, 2023 · From the USPTO record
Lapsed on the fee recordEnded Apr 14, 2023From the USPTO record
US 8,952,155Rilpivirine process
Lapsed on the fee record
Ended Feb 10, 2023 · From the USPTO record
Lapsed on the fee recordEnded Feb 10, 2023From the USPTO record
US 7,858,801Process for producing enantiomer of amlodipine in high optical purity
Lapsed on the fee record
Ended Dec 28, 2022 · From the USPTO record
Lapsed on the fee recordEnded Dec 28, 2022From the USPTO record
US 8,686,165Process for preparation of taxane derivatives
Lapsed on the fee record
Ended Apr 1, 2022 · From the USPTO record
Lapsed on the fee recordEnded Apr 1, 2022From the USPTO record
US 9,919,993Process for preparation of acitrecin
Lapsed on the fee record
Ended Mar 20, 2022 · From the USPTO record
Lapsed on the fee recordEnded Mar 20, 2022From the USPTO record
US 8,604,189Process for the preparation of Efavirenz
Lapsed on the fee record
Ended Dec 10, 2021 · From the USPTO record
Lapsed on the fee recordEnded Dec 10, 2021From the USPTO record
US 8,569,544Process for preparation of benzphetamine and its pharmaceutically acceptable salts
Lapsed on the fee record
Ended Oct 29, 2021 · From the USPTO record
Lapsed on the fee recordEnded Oct 29, 2021From the USPTO record
US 8,445,688Process for producing enantiomer of amlodipine in high optical purity
Lapsed on the fee record
Ended May 21, 2021 · From the USPTO record
Lapsed on the fee recordEnded May 21, 2021From the USPTO record
US 9,522,924Pyridone derivatives as acid secretion inhibitors and process for preparation thereof
Lapsed on the fee record
Ended Dec 20, 2020 · From the USPTO record
Lapsed on the fee recordEnded Dec 20, 2020From the USPTO record
US 9,480,681Controlled release formulations of nisoldipine
Lapsed on the fee record
Ended Nov 1, 2020 · From the USPTO record
Lapsed on the fee recordEnded Nov 1, 2020From the USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited